Skip to main content
Top
Published in: Clinical Research in Cardiology 1/2016

01-01-2016 | Original Paper

Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy

Authors: Simon Greulich, Ingrid Kindermann, Julia Schumm, Andrea Perne, Stefan Birkmeier, Stefan Grün, Peter Ong, Tim Schäufele, Karin Klingel, Steffen Schneider, Reinhard Kandolf, Michael Böhm, Udo Sechtem, Heiko Mahrholdt

Published in: Clinical Research in Cardiology | Issue 1/2016

Login to get access

Abstract

Objective

Primary objective was to establish the prognostic value of the myocardial load of PVB19 genomes in patients presenting for work-up of myocarditis and/or unclear cardiomyopathy in comparison to clinical, and CMR parameters.

Methods

108 consecutive patients who underwent EMB because of suspected myocarditis and/or unclear cardiomyopathy, and had evidence of myocardial PVB19 genome, were enrolled. Primary endpoint was all-cause mortality; secondary endpoint was a composite of cardiac mortality and hospitalization for heart failure.

Results

Mean LV-EF was 40 %. We found n = 27 patients to have a viral load ≥500 GE (IQR 559–846), n = 72 had 100–499 GE, and n = 9 had <100 GE. Immunohistology revealed chronic myocarditis in n = 66, acute myocarditis in n = 1, DCM in n = 17, PVB19 genome only in n = 13, and other pathologies in n = 11. During follow-up 11 patients died, two suffered SCD but were successfully shocked by ICD, and 21 were hospitalized for heart failure. Interestingly, not the viral load, but functional parameters such as LV-EF, LV-EDV (endpoint 2), as well as the histologic diagnosis of DCM and the presence of LGE (for all endpoints) reached statistical significance. In fact, the presence of LGE yields an odds-ratio for a lethal event of 8.56 (endpoint 1), and of 5.52 for endpoint 2. No patient with normal LV-EF, or the absence of LGE, suffered cardiac death during long-term follow-up.

Conclusion

The viral load of PVB19 genomes in the myocardium is not related to the long-term outcome. Furthermore, this study suggests a growing role of imaging for risk stratification in non-ischemic myocardial disease.
Literature
1.
2.
go back to reference Saphir O (1941) Myocarditis: a general review, with an analysis of 240 cases. Arch Pathol 32:1000–1051 Saphir O (1941) Myocarditis: a general review, with an analysis of 240 cases. Arch Pathol 32:1000–1051
3.
go back to reference Cooper LT, Jr. Myocarditis (2009) The New England journal of medicine 360:1526–38 Cooper LT, Jr. Myocarditis (2009) The New England journal of medicine 360:1526–38
4.
go back to reference Kindermann I, Kindermann M, Kandolf R et al (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648PubMedCrossRef Kindermann I, Kindermann M, Kandolf R et al (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648PubMedCrossRef
5.
go back to reference Grun S, Schumm J, Greulich S et al (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59:1604–1615PubMedCrossRef Grun S, Schumm J, Greulich S et al (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59:1604–1615PubMedCrossRef
6.
go back to reference Bock CT, Klingel K, Kandolf R (2010) Human parvovirus B19-associated myocarditis. New Engl J Med 362:1248–1249PubMedCrossRef Bock CT, Klingel K, Kandolf R (2010) Human parvovirus B19-associated myocarditis. New Engl J Med 362:1248–1249PubMedCrossRef
7.
go back to reference Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(2636–48):2648a–2648d Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(2636–48):2648a–2648d
8.
go back to reference Stewart GC, Lopez-Molina J, Gottumukkala RV et al (2011) Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 4:71–78PubMedPubMedCentralCrossRef Stewart GC, Lopez-Molina J, Gottumukkala RV et al (2011) Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 4:71–78PubMedPubMedCentralCrossRef
9.
go back to reference Mahrholdt H, Goedecke C, Wagner A et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258PubMedCrossRef Mahrholdt H, Goedecke C, Wagner A et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258PubMedCrossRef
10.
go back to reference Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2008) Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 10:35PubMedPubMedCentralCrossRef Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2008) Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 10:35PubMedPubMedCentralCrossRef
11.
go back to reference Simonetti OP, Kim RJ, Fieno DS et al (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218:215–223PubMedCrossRef Simonetti OP, Kim RJ, Fieno DS et al (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218:215–223PubMedCrossRef
12.
go back to reference Mahrholdt H, Wagner A, Holly TA et al (2002) Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106:2322–2327PubMedCrossRef Mahrholdt H, Wagner A, Holly TA et al (2002) Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106:2322–2327PubMedCrossRef
13.
go back to reference Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156–2164PubMedCrossRef Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156–2164PubMedCrossRef
14.
go back to reference Mahrholdt H, Wagner A, Deluigi CC et al (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114:1581–1590PubMedCrossRef Mahrholdt H, Wagner A, Deluigi CC et al (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114:1581–1590PubMedCrossRef
15.
16.
go back to reference Dennert R, van Paassen P, Wolffs P et al (2012) Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol 19:1182–1187PubMedPubMedCentralCrossRef Dennert R, van Paassen P, Wolffs P et al (2012) Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol 19:1182–1187PubMedPubMedCentralCrossRef
17.
go back to reference Norja P, Hokynar K, Aaltonen LM et al (2006) Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci USA 103:7450–7453PubMedPubMedCentralCrossRef Norja P, Hokynar K, Aaltonen LM et al (2006) Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci USA 103:7450–7453PubMedPubMedCentralCrossRef
18.
go back to reference Di Bella G, Florian A, Oreto L et al (2012) Electrocardiographic findings and myocardial damage in acute myocarditis detected by cardiac magnetic resonance. Clin Res Cardiol 101(8):617–624PubMedCrossRef Di Bella G, Florian A, Oreto L et al (2012) Electrocardiographic findings and myocardial damage in acute myocarditis detected by cardiac magnetic resonance. Clin Res Cardiol 101(8):617–624PubMedCrossRef
19.
go back to reference Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875–887PubMedCrossRef Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875–887PubMedCrossRef
20.
go back to reference Schenk T, Enders M, Pollak S, Hahn R, Huzly D (2009) High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 47:106–110PubMedPubMedCentralCrossRef Schenk T, Enders M, Pollak S, Hahn R, Huzly D (2009) High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 47:106–110PubMedPubMedCentralCrossRef
21.
go back to reference Mason JW, O’Connell JB, Herskowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. New Engl J Med 333:269–275PubMedCrossRef Mason JW, O’Connell JB, Herskowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. New Engl J Med 333:269–275PubMedCrossRef
22.
go back to reference Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med 352:225–237PubMedCrossRef Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med 352:225–237PubMedCrossRef
23.
go back to reference Greulich S, Deluigi CC, Gloekler S et al (2013) CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovas Imaging 6:501–511CrossRef Greulich S, Deluigi CC, Gloekler S et al (2013) CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovas Imaging 6:501–511CrossRef
24.
go back to reference Schumm J, Greulich S, Wagner A et al (2014) Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 16:14PubMedPubMedCentralCrossRef Schumm J, Greulich S, Wagner A et al (2014) Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 16:14PubMedPubMedCentralCrossRef
Metadata
Title
Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy
Authors
Simon Greulich
Ingrid Kindermann
Julia Schumm
Andrea Perne
Stefan Birkmeier
Stefan Grün
Peter Ong
Tim Schäufele
Karin Klingel
Steffen Schneider
Reinhard Kandolf
Michael Böhm
Udo Sechtem
Heiko Mahrholdt
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 1/2016
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0884-6

Other articles of this Issue 1/2016

Clinical Research in Cardiology 1/2016 Go to the issue